BRL 303 Enters a China Rare Disease Development Pilot
China’s Center for Drug Evaluation included BRL Medicine’s BRL-303 (TyU19), a donor-derived CD19 CAR-T product, in its rare-disease Care Plan-Extension pilot on October 8. BRL disclosed the decision on October 9 alongside an earlier…
